A

ACAD

ACAD

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
0%Bearish
Buy/Sell Ratio0% buys
BearishBullish
ACAD Live QuoteReal-time
$17.59
$2.60(-12.88%)1M
Day Range$17.44 – $17.96
Open$17.74
Previous Close$17.83
Volume1.45M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$3.08B
P/E Ratio (TTM)8.4
Forward P/E20.6
EPS (TTM)$2.12
Price to Book2.3
Dividend Yield0.65%
Beta (Volatility)0.89
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $17.59 (11%)
Low: $15.86High: $30.96
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$30.21-79.9% upside

Insider Buys

0

$0

Insider Sales

1

$69K

Total Volume

$69K

1 transactions

Net Activity

$69K

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
35CONFIDENCE

Sentiment Rating

Moderate Distribution

CEO Conviction Index

No Recent Signal

Key Drivers

  • •Heavy distribution: sales represent 100% of total transaction value.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
S
1

Schneyer Mark C.

EVP, CFO

0 buys1 sells

$69K total

Trading History
ACAD insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Oct 30, 2026

3 weeks ago

Schneyer Mark C.

EVP, CFO

CFO
Sell3.3K$20.88$69K
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
ACAD Buy Conviction0%
Industry Rank#0 of 569
Volume Contribution0.0%
Total Industry Activity$16.53B

ACAD has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for ACAD

Over the last 90 days, corporate insiders at ACAD (ACAD) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 1 were sales. The total volume of insider trading reached $69K.

The net insider activity for ACAD shows a net selling bias of $69K. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Schneyer Mark C. (EVP, CFO), who traded 3.3K shares valued at $69K on Oct 30, 2026.

Live Market News & Developments
Aggregated real-time headlines for ACAD (ACAD)
6 updates

symbol__ Stock Quote Price and Forecast

CNNYesterday

Acadia Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History

Yahoo! Finance Canada2d ago

Acadia Pharmaceuticals Inc. (ACAD) stock price, news, quote and history

Yahoo Finance Australia2d ago

ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal

TradingView56d ago

ACAD - Acadia Pharmaceuticals Inc Stock Price and Quote

Finviz177d ago

Acadia Pharmaceuticals (ACAD) Stock Dropped, So What Is Driving Attention Now?

Simply Wall St25d ago

FAQs About ACAD Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for ACAD.

Based on SEC Form 4 disclosures, the Insider Confidence Score for ACAD is currently 35/100, which reflects a moderate distribution bias. This calculation accounts for a total of 0 purchases and 1 sales by company executives over the last 90 days.

The CEO Conviction Index for ACAD is rated as "No Recent Signal". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.